SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in ChinaPhase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer | Lee's Pharmaceutical
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
